CD8A and neoplasm: Notably, PD-L1, expressed by tumor cells, interacts with PD-1 receptors on CD8+ T cells, thus suppressing their activity [33]; it is underlined that the interaction of PD-L1/PD-1 is a pharmacological target of immunotherapy against many types of cancer, including HCC [34].